about
Multivalent supramolecular dendrimer-based drugs.Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis.IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease.Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats.Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic painCR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats.Progress towards the identification of new aggrecanase inhibitors.Experimental pharmacology of glucosamine sulfate.Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity.Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.Design, synthesis, and preliminary biological evaluation of pyrrolo[3,4-c]quinolin-1-one and oxoisoindoline derivatives as aggrecanase inhibitors.Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers.Antihistaminic/antiallergic activity of 2-dialkylaminoalkylthio(oxy)-1-substituted benzimidazoles: evaluation "in vitro" and "in vivo".Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.Andolast acts at different cellular levels to inhibit immunoglobulin E synthesis.The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endDesign, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist.Phenylindenone isomers as divergent modulators of p38α MAP kinase.Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.Synthesis and structure-activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold.Effectiveness of carbocysteine lysine salt monohydrate on models of airway inflammation and hyperresponsiveness.Tartronates: a new generation of drugs affecting bone metabolismEFFICACY OF A NEW TOPICAL GEL-SPRAY FORMULATION OF KETOPROFEN LYSINE SALT IN THE RAT: PERCUTANEOUS PERMEATIONIN VITROANDIN VIVOAND PHARMACOLOGICAL ACTIVITYSynthesis, inhibitory activity towards human leukocyte elastase and molecular modelling studies of 1-carbamoyl-4-methyleneaminoxyazetidinonesDendrimeric tetravalent ligands for the serotonin-gated ion channelMultivalent ligands for the serotonin 5-HT receptorIL-1 beta primes IL-8-activated human neutrophils for elastase release, phospholipase D activity, and calcium fluxProstaglandins and lipolysis I: PGI2 formation by rat epididymal adipose tissue arteryPeripheral blood mononuclear cell production of interleukin-8 and IL-8-dependent neutrophil function in hypercholesterolemic patientsDoes colchicine really induce bone formation in the rodent bone Marrow? Yes, it doesLipopolysaccharide-induced lung injury in mice. I. Concomitant evaluation of inflammatory cells and haemorrhagic lung damageLipopolysaccharide-induced lung injury in mice. II. Evaluation of functional damage in isolated parenchyma stripsLps induces IL-6 in the brain and in serum largely through TNF productionRole of tumor necrosis factor-alpha in endotoxin-induced lung parenchymal hyporesponsiveness in miceSynthesis and in vitro and in vivo evaluation of the 2-(6'methoxy-3',4'-dihydro-1'-naphtyl)-4H-3,1-benzoxazin-4- one as a new potent substrate inhibitor of human leukocyte elastasePharmacokinetic study of a new angiotensin-AT1 antagonist by HPLCSynthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptorImproved efficacy, tolerance, safety and abuse liability profile of the combination CR4056-morphine over morphine alone in rodent models
P50
Q33517157-18061D6A-16FE-40BC-A7F3-329611AE9465Q33650279-F2636BBB-CB95-4131-8AE7-D4856834D70CQ33715791-5C17711B-DA51-42E3-B68E-3956DBCDB029Q34025170-2D3B3BDC-001C-4ED9-8CDC-B4D5E3AF075DQ34999759-8ED6D36E-1B73-4DFE-A586-65D94C938BB2Q36084704-8EB11D66-C859-4CEE-9961-F8B8AF34FA3AQ37550676-416B0CF0-1CD2-4F82-8BA4-EA573865CFFDQ38684643-B6B5390A-B6DF-4AD0-960F-0A680BBCBD39Q39778292-B37FC3D7-9357-4B6D-B075-9838FA378C1AQ40735252-BEEFED74-62F7-4E21-AA0D-EBC1142AA2EAQ42712600-87CF1631-87D4-424F-BBCC-6DFB72EF1700Q43105023-692956FD-ADFE-4C3F-A22A-94F436A0DD61Q43593923-CD4B1297-9380-4C58-BD6A-C4BDBD655478Q43612318-087A164C-A9A1-4342-A2D8-0B9401985DBDQ45149103-A49EAF49-83AD-4816-BB29-FFD730E4AA7FQ46077162-0E8794E9-D54A-4B41-A537-7BFD77918938Q46212849-5D01021E-5AA7-4A74-9156-B62B040B8609Q46719815-2F86E7FE-2BE6-439D-ABD6-BB8245D4B1D6Q46763265-42EBE734-8FEB-45B7-8E1F-080103CBCCCBQ51389372-94F380CE-713A-42C8-ABF2-52EA62F66ACFQ52680975-52794861-9BC7-401A-A9CF-36EA24FE0135Q53842126-74B61D66-C400-4677-B281-896E068CB2A3Q55066528-61E76011-0CBF-4346-92B8-4BA953399E9BQ57103091-990E01A8-8D48-4AE8-8385-F2F5F70365B1Q58825179-C1D9AD0E-4EF9-401C-9A7A-6EBB88492D63Q58960308-1B194239-7030-483C-863A-91E2011D0A9FQ59613729-37944A56-9532-4EFC-ADA7-933DD343F08AQ60513791-EAC30E48-2806-424A-BE9D-4A34BEE951D6Q71007645-B5275596-6114-4764-A558-BB08A97D347DQ71572096-0A4A1A9F-38CD-4F25-84F2-07D0FE5B0F81Q73110406-DC4A3093-5361-4880-B4A3-A95D5AEABC6BQ73132778-C3441E36-5043-4531-8A39-B4139EC203BBQ73754332-A85A2EE6-4032-4156-8FE9-093EF7C51C23Q73754342-D51803F9-4103-4972-B948-22576360EA25Q74126967-D11DE949-6C5E-476C-BE54-6AFC52B26434Q74613503-805AFCF9-10E9-4436-8696-37C5020A4B66Q77788042-CC3087EB-DF90-47E9-900F-40E69B35792DQ81364924-A59D36E3-DD5C-4F3F-81C8-19600D92BBDAQ84963719-84763AE0-7021-4695-AB1F-E88D23C7E5F4Q90185275-E6531C89-EB8D-43B6-8E23-4889B7004FC5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gianfranco Caselli
@ast
Gianfranco Caselli
@en
Gianfranco Caselli
@es
Gianfranco Caselli
@nl
type
label
Gianfranco Caselli
@ast
Gianfranco Caselli
@en
Gianfranco Caselli
@es
Gianfranco Caselli
@nl
prefLabel
Gianfranco Caselli
@ast
Gianfranco Caselli
@en
Gianfranco Caselli
@es
Gianfranco Caselli
@nl
P106
P1153
7006498708
P31
P496
0000-0002-1075-7408